NCT00671671View on ClinicalTrials.gov

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hepatitis, ChronicHepatitis C Virus
Interventions
DRUG

Small Molecule Agent (PF-868554)

Study drug will be administered 700mg BID in the fed state for three days.

DRUG

Small Molecule Agent (PF-868554)

Study drug will be given 450mg BID for a duration of 10 days.

Trial Locations (1)

32608

Pfizer Investigational Site, Gainesville

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00671671 - Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. | Biotech Hunter | Biotech Hunter